MedTrace Logo

Efficacy of Lu 31-130 in Patients With Schizophrenia

NCT00768326 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2016-11-08

No results posted yet for this study

Summary

The main purpose with the study is to evaluate the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to placebo.

Conditions

Interventions

DRUG

Zicronapine

Study Part A: 3mg; orally, film-coated tablets, once daily, 8 weeks

DRUG

Zicronapine

Study Part B: 5mg; orally, film-coated tablets, once daily, 8 weeks

DRUG

Zicronapine

Study Part C: 7mg; orally, film-coated tablets, once daily, 8 weeks

DRUG

Zicronapine

Study Part D: 2 x 5mg; orally, film-coated tablets, once daily, 8 weeks

DRUG

Zicronapine

Study Part E: 2 x 7mg; orally, film-coated tablets, once daily, 8 weeks

DRUG

Placebo

Study Part A, B, C, D and E: Placebo; orally, film-coated tablets, once daily, 8 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768326 on ClinicalTrials.gov